Synopsis The conventional treatment of ST-segment elevation myocardial infarction (STEMI) patients with primary percutaneous coronary intervention (PPCI), current P2Y12 platelet inhibitors do not provide maximal platelet inhibition at the time of reperfusion. The aim of the study is to investigate whether administering cangrelor prior to reperfusion, can prevent microvascular obstruction (MVO) and reduce acute MI size, assessed by Cardiovascular Magnetic Resonance (CMR), in STEMI patients treated with PPCI. This week’s “MED FACT” discusses a clinical trial from Journal Clinical Cardiology, “ Platelet inhibition target reperfusion trial: Rationale and study design”. Authors : Heerajnarain Bulluck1,2,3 | Mervyn H.
H. Chan4 | Jennifer A. Bryant3 Et al Key Takeaways: Objective: To assess whether cangrelor administered prior to reperfusion would reduce acute MI size and prevent MVO, as…
